Fibrinolytic Agents

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. 
  • A perspective on the regulation of the evaluation of new antithrombotic drugs. 
  • A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. 
  • A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome. 
  • A risk score to predict bleeding in patients with acute coronary syndromes. 
  • A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. 
  • A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application. 
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. 
  • Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. 
  • Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. 
  • Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute coronary syndromes: Right direction--moving proximally in timing of STEMI care. 
  • Acute ischemic heart disease. 
  • Acute ischemic stroke treatment in 2007. 
  • Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. 
  • Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry. 
  • Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. 
  • Adoption of thrombolytic therapy in the management of acute myocardial infarction. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. 
  • Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. 
  • Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. 
  • An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. 
  • Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. 
  • Antithrombin alternatives in STEMI. 
  • Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement: Trials Evaluating Patient-Centered Outcomes Needed. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft. 
  • Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. 
  • Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. 
  • Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. 
  • Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. 
  • Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. 
  • Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. 
  • Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. 
  • Antithrombotic therapy after prosthetic cardiac valve implantation: improving postoperative, long-term patient management. Introduction. 
  • Antithrombotic therapy and invasive procedures. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician. 
  • Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. 
  • Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? 
  • Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). 
  • Antithrombotic therapy in atrial fibrillation. 
  • Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. 
  • Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. 
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy in patients undergoing percutaneous coronary intervention. 
  • Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. 
  • Antithrombotic therapy practices in US hospitals in an era of practice guidelines. 
  • Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. 
  • Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. 
  • Antithrombotic therapy: new areas to understand efficacy and bleeding. 
  • Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. 
  • Antithrombotic treatment strategies after PCI. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Aspirin in cardiovascular disorders. What is the optimum dose? 
  • Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. 
  • Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. 
  • Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. 
  • Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. 
  • Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. 
  • Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. 
  • Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. 
  • Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. 
  • Atrial Fibrillation and Percutaneous Coronary Intervention. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. 
  • Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? 
  • Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. 
  • Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. 
  • Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. 
  • Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. 
  • Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. 
  • Blood coagulation: hemostasis and thrombin regulation. 
  • Bolus fibrinolysis: risk, benefit, and opportunities. 
  • Canadian Consensus Conference on Coronary Thrombolysis--1994 update. 
  • Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. 
  • Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. 
  • Cardiogenic shock complicating acute coronary syndromes. 
  • Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis. 
  • Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. 
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. 
  • Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. 
  • Chronic kidney disease and stroke. 
  • Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. 
  • Clinical Policy: Emergency Department Management of Patients Needing Reperfusion Therapy for Acute ST-Segment Elevation Myocardial Infarction. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical implications for patients on antithrombotic therapy while taking supplements. 
  • Clinical outcomes according to time to treatment. 
  • Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. 
  • Clinical trials of restenosis after coronary angioplasty. 
  • Clinical use of novel antithrombotic agents in the management of acute coronary syndromes. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Clopidogrel does not induce fibrinolysis in healthy subjects. 
  • Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. 
  • Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). 
  • Combination antithrombotic therapies. 
  • Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. 
  • Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 
  • Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. 
  • Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. 
  • Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. 
  • Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. 
  • Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Compromised atrial coronary anatomy is associated with atrial arrhythmias and atrioventricular block complicating acute myocardial infarction. 
  • Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. 
  • Contemporary pharmacological reperfusion in ST elevation myocardial infarction. 
  • Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. 
  • Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. 
  • Coronary bypass grafting after failed elective and failed emergent percutaneous angioplasty. Relative risks of emergent surgical intervention. 
  • Coronary revascularization after thrombolytic therapy for myocardial infarction: what caseloads could Canadian centres face? 
  • Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction. 
  • Cost-effectiveness considerations in the treatment of essential thrombocythemia. 
  • Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). 
  • Critical concepts in cost-effectiveness for cardiovascular specialists. 
  • Current evidence and clinical implications of aspirin resistance. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). 
  • D-Dimer elevation and adverse outcomes. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? 
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 
  • Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. 
  • Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. 
  • Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. 
  • Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. 
  • Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. 
  • Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. 
  • Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Dialogue with patient care organizations. 
  • Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. 
  • Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? 
  • Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. 
  • Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. 
  • Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. 
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 
  • Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. 
  • Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. 
  • Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. 
  • Early intervention: which patients and how early? 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Economic assessment of thrombocytopenia: CATCH Registry. 
  • Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. 
  • Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study. 
  • Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. 
  • Effect of a Triage-Based Screening Protocol on Diagnosis and Treatment of Acute Coronary Syndrome in a Tanzanian Emergency Department: A Prospective Pre-Post Study. 
  • Effect of age on outcome with primary angioplasty versus thrombolysis. 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. 
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. 
  • Effect of streptavidin-biotin on endothelial vasoregulation and leukocyte adhesion. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. 
  • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. 
  • Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. 
  • Emergency medical services use and its association with acute ischaemic stroke evaluation and treatment in Singapore. 
  • Emergency medicine in the Veterans Health Administration-results from a nationwide survey. 
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. 
  • Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. 
  • Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. 
  • Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). 
  • Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. 
  • Enoxaparin vs unfractionated heparin in acute coronary syndrome. 
  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Evaluation and management of blunt cerebrovascular injury: A practice management guideline from the Eastern Association for the Surgery of Trauma. 
  • Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism. 
  • Evaluation of p-amidinophenyl esters as potential antithrombotic agents. 
  • Evidence for the involvement of metalloendoproteases in the acrosome reaction in sea urchin sperm. 
  • Evidence supporting secondary prevention strategies. 
  • Evidence-Based Performance Measures and Outcomes in Patients With Acute Ischemic Stroke. 
  • Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. 
  • Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. 
  • Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). 
  • Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitated versus primary PCI for acute myocardial infarction. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. 
  • Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolysis or primary PCI in myocardial infarction. 
  • Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. 
  • Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • Filtering bleb thrombolysis with tissue plasminogen activator. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • From thrombolytic megatrials to clinical policy-making: facing the facts. 
  • Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. 
  • Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. 
  • Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. 
  • Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. 
  • Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. 
  • Guidelines on the use of thrombolytic agents in stroke. 
  • Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. 
  • Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin in acute coronary disease--requiem for a heavyweight? 
  • Heparin management in acute myocardial infarction (AMI). 
  • Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. 
  • Heparin-coated stents do not protect cancer patients from cardiac complications after noncardiac surgery. 
  • Heparin-induced thrombocytopenia in the pediatric intensive care unit population. 
  • Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. 
  • High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. 
  • High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Hospital Factors Associated With Interhospital Transfer Destination for Stroke in the Northeast United States. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • How can modeling best contribute to the assessment of secondary stroke prevention strategies? 
  • How much do we gain by reducing time to reperfusion therapy? 
  • Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. 
  • Hyperdense posterior cerebral artery sign in a setting of spontaneous vertebral artery dissection: a blessing in disguise? 
  • IV tPA for acute ischemic stroke: Times are changing. 
  • Identification of patients at high risk for post-discharge venous thromboembolism after hepato-pancreato-biliary surgery: which patients benefit from extended thromboprophylaxis? 
  • Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. 
  • Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. 
  • Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. 
  • Implications of bleeding and blood transfusion in percutaneous coronary intervention. 
  • Important patient subgroups in thrombolytic therapy. 
  • Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. 
  • Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. 
  • In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. 
  • In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. 
  • In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors. 
  • Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. 
  • Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. 
  • Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. 
  • Inhibition of intimal hyperplasia by direct thrombin inhibitors in an animal vein bypass model. 
  • Inhibition of radiation-induced up-regulation of leukocyte adhesion to endothelial cells with the platelet-activating factor inhibitor, BN52021. 
  • Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? 
  • Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. 
  • International differences in evolution of early discharge after acute myocardial infarction. 
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. 
  • Interventional and new approaches to stroke prevention: introduction. 
  • Intra-arterial thrombolytic therapy in peri-coronary angiography ischemic stroke. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin. 
  • Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis. 
  • Intravenous Tissue Plasminogen Activator in Stroke Mimics. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Intravenous thrombolysis in acute myocardial infarction. 
  • Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy. 
  • Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 
  • Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s? 
  • Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. 
  • Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. 
  • Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. 
  • Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. 
  • Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. 
  • Lessons learned from the CRUSADE National Quality Improvement Initiative. 
  • Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke. 
  • Long-term adherence with cardiovascular drug regimens. 
  • Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 
  • Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. 
  • Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease. 
  • Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. 
  • Major bleeding: management and risk reduction in acute coronary syndromes. 
  • Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. 
  • Management of acute coronary syndromes in patients with renal dysfunction. 
  • Management of cardiogenic shock. 
  • Manual high-dose regional intraoperative thrombolysis of lower extremity emboli after open repair of a ruptured abdominal aortic aneurysm. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. 
  • Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. 
  • Meta-analysis of multitreatment studies. 
  • Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. 
  • Modern medical management of acute ischemic stroke. 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Myocardial reperfusion: is it ever too late? 
  • N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 
  • Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. 
  • Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. 
  • New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • New antithrombotics. 
  • New dose regimens for coronary thrombolysis. 
  • New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. 
  • Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. 
  • Next-generation antithrombin therapies. 
  • Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. 
  • Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. 
  • Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. 
  • Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. 
  • Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. 
  • Nucleic acid scavengers inhibit thrombosis without increasing bleeding. 
  • Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. 
  • One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. 
  • Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. 
  • Optimising outcomes: socioeconomic perspective. 
  • Optimizing heparin compounds: a working construct for future antithrombotic drug development. 
  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction. 
  • Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • PCI at non-PCI centres: immediate or rescue? 
  • Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. 
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 
  • Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm. 
  • Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. 
  • Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. 
  • Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 
  • Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Percutaneous interventions on the hemodialysis reliable outflow vascular access device. 
  • Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. 
  • Percutaneous revascularization of chronic coronary occlusions: an overview. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. 
  • Perspectives gained from large-scale thrombolytic comparative trials. 
  • Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry. 
  • Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. 
  • Pharmacologic preservation of the hemostatic system during cardiac surgery. 
  • Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. 
  • Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study. 
  • Pharmacotherapy: Intracoronary streptokinase in acute myocardial infarction. 
  • Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. 
  • Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. 
  • Platelet activation in myocardial ischemic syndromes. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. 
  • Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty? 
  • Poststroke pharmacotherapy: another ictus. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. 
  • Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. 
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. 
  • Predictors of rapid brain imaging in acute stroke: analysis of the Get With the Guidelines-Stroke program. 
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. 
  • Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis. 
  • Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. 
  • Preventing VTE in Outpatients With Cancer. 
  • Prevention and management of venous thromboembolism in pregnancy. 
  • Prevention and treatment of deep venous thrombosis. 
  • Prevention of Cardiogenic Shock After Acute Myocardial Infarction. 
  • Prevention of Stroke in Atrial Fibrillation After Coronary Stenting. 
  • Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. 
  • Primum non nocere: antithombotics after intracerebral hemorrhage? 
  • Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. 
  • Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 
  • Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. 
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. 
  • Prosthetic valve thrombosis: when and how should we lyse? 
  • Protein-binding oligonucleotides: the next frontier in antithrombotic therapy. 
  • Pulmonary artery thrombus in a premature neonate treated with recombinant tissue plasminogen activator. 
  • Pursuing progress in acute coronary syndromes. 
  • Pursuit of the Optimal Antithrombotic Regimen for Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Who Undergo Subsequent Percutaneous Coronary Intervention. 
  • Quality of Care and Outcomes for Patients With Stroke in the United States Admitted During the International Stroke Conference. 
  • ROC methodology within a monitoring framework. 
  • Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. 
  • Radiologic intervention in the acute stroke patient. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Rapid intra-arterial thrombolysis in stent-associated retinal artery occlusion. 
  • Rate of Symptomatic Intracerebral Hemorrhage Related to Intravenous tPA Administered Over Telestroke Within 4.5-Hour Window. 
  • Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. 
  • Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. 
  • Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. 
  • Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo. 
  • Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke. 
  • Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). 
  • Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship between age and platelet activation in patients with stable and unstable angina. 
  • Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Relationship between community hospital versus pre-hospital location of randomisation and clinical outcomes in ST-elevation myocardial infarction patients: insights from the Stream study. 
  • Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. 
  • Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. 
  • Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. 
  • Reperfusion synergism: will it be both sustained and safe? 
  • Response to the Letter to the Editor titled "Atrial fibrillation in patients with acute coronary syndromes". 
  • Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. 
  • Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. 
  • Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. 
  • Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. 
  • Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. 
  • Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. 
  • Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Routine 24-Hour Computed Tomography Brain Scan is not useful in stable patients Post Intravenous Tissue Plasminogen Activator. 
  • ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • ST-segment-elevation myocardial infarction treatment and the seductive lure of observational analyses. 
  • Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. 
  • Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke. 
  • Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. 
  • Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke: A Single-Center Experience. 
  • Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. 
  • Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. 
  • Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial. 
  • Screening with MRI for Accurate and Rapid Stroke Treatment: SMART. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. 
  • Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. 
  • Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. 
  • Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? 
  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 
  • Statewide assessment of hospital-based stroke prevention and treatment services in North Carolina: changes over the last 5 years. 
  • Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. 
  • Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. 
  • Stent-assisted basilar reconstruction for a traumatic vertebral dissection with a large basilar artery thrombosis. 
  • Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report. 
  • Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. 
  • Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. 
  • Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Stroke prevention in atrial fibrillation. 
  • Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. 
  • Surface projections of titanium substrates increase antithrombotic endothelial function in response to shear stress. 
  • Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. 
  • Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. 
  • Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. 
  • Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. 
  • Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. 
  • Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. 
  • Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit. 
  • Target: Stroke Was Associated With Faster Intravenous Thrombolysis and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries. 
  • Targeting telestroke: benchmarking time performance in telestroke consultations. 
  • Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies. 
  • Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. 
  • Temporal changes in the external validity of clinical trials: asymptomatic carotid artery stenosis. 
  • Temporal trends in medical therapies for ST- and non-ST elevation myocardial infarction: (from the Atherosclerosis Risk in Communities [ARIC] Surveillance Study). 
  • The Choice Is Reperfusion Therapy: But Which One? 
  • The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. 
  • The Effect of Ex Situ Perfusion in a Swine Limb Vascularized Composite Tissue Allograft on Survival up to 24 Hours. 
  • The Evolving Post-PCI Antithrombotic Therapies. 
  • The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. 
  • The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. 
  • The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients. 
  • The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. 
  • The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale. 
  • The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of plasmin on the subunit structure of human fibrinogen. 
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. 
  • The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? 
  • The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia. 
  • The management of acute coronary syndromes in patients with chronic kidney disease. 
  • The many faces of the contact pathway and their role in thrombosis. 
  • The need for wider utilization of thrombolytic therapy. 
  • The next 10 years in personalized medicine in cardiology. 
  • The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy. 
  • The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. 
  • The pathogenesis of vascular thrombosis and its impact in microvascular surgery. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The platelet-related effects of tenecteplase versus alteplase versus reteplase. 
  • The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The rationale for thrombolytic therapy. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The reply. 
  • The role of aspirin in cardiovascular diseases--forgotten benefits? 
  • The role of fibrinolytics in the prehospital treatment of ST-elevation myocardial infarction (STEMI). 
  • The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. 
  • The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. 
  • The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. 
  • The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. 
  • The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombin-Induced Inflammation in Human Decidual Cells Is Not Affected By Heparin. 
  • Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. 
  • Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. 
  • Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Thrombolysis for acute ischemic stroke in patients with cancer: a population study. 
  • Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. 
  • Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke. 
  • Thrombolytic therapy and unstable angina. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Thrombolytic therapy for wake-up stroke: A systematic review and meta-analysis. 
  • Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. 
  • Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. 
  • Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. 
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. 
  • Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. 
  • Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. 
  • Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. 
  • Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. 
  • Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. 
  • To transfer or not to transfer: acute myocardial infarction reperfusion. 
  • TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Transradial approach for coronary angiography and interventions: results of the first international transradial practice survey. 
  • Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. 
  • Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. 
  • Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends and Outcomes of Fibrinolytic Therapy for STEMI: Insights and Reflections in the COVID-19 Era. 
  • Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. 
  • Use of a Smartphone Platform to Help With Emergency Management of Acute Ischemic Stroke: Observational Study. 
  • Use of antithrombotic medications among elderly ischemic stroke patients. 
  • Use of common antiplatelet drugs for vascular diseases. 
  • Use of emergency department transcranial Doppler assessment of reperfusion after intravenous tPA for ischemic stroke. 
  • Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarcts. 
  • Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. 
  • Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). 
  • Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction. 
  • Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? 
  • Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? 
  • Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. 
  • Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. 
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. 
  • Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. 
  • What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? 
  • Who should have a routine early invasive approach after fibrinolytic therapy? 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. 
  • [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome]. 
  • mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Esclamado, Ramon Mitra, Professor Emeritus of Head and Neck Surgery and Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Kim, Charles Yoon, Professor of Radiology, Radiology, Interventional Radiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology